Appendix 2 : Summary of Excluded Studies

Study	Reason for exclusion
Ashenden M, Gore C, Dobson G, et al. Simulated moderate altitude elevates serum erythropoietin but does not increase reticulocyte production in well-trained runners. *Eur J Appl Physiol.* 2000;81(5):428-35.	Inappropriate intervention (e.g. co-intervention or a non-EPO agent used)
Ashenden MJ, Hahn AG, Martin DT, et al. A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration. *J Sport Sci*. 2001;19(11):831-7.	
Baumann C, Bond K, Rupp J, et al. Echinacea Purpurea Supplementation does not Enhance VO2max in Distance Runners. Journal of Strength and Conditioning Research. *J Strength Cond Res.* 2014;28(5):1367-72.	
Baumann C, Kwak D. Echinacea supplementation: does it really improve aerobic fitness? *J Exerc Nutrition Biochem.* 2016;20(3):1-6.	
Bellar D, Moody K, Richard N, et al. Efficacy of a Botanical Supplement with Concentrated Echinacea purpurea for Increasing Aerobic Capacity. *ISRN Nutr.* 2014;149549.	
Borisch S, Baertsch P, Friedmann B. Effects of strength endurance training in hypoxia on endurance capacity, blood volume on erythropoietin. *Int J Sports Med.* 2002;23(Suppl.2):S80.	
Brugniaux J, Schmitt L, Robach P, et al. Eighteen days of "living high, training low" stimulate erythropoiesis and enhance aerobic performance in elite middle-distance runners. *J Appl Physiol.* 2006;100(1):203-11.	
Marchand A, Martin JA, Collot D, et al. Combined administration of microdoses of growth hormone and erythropoietin: Effects on performance and evaluation of GH detection capability using anti-doping methods. *Drug Test Anal.* 2019. doi:10.1002/dta.2674.	
Parisotto R, Gore CJ, Emslie KR, et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes.	

Appendix 2: Summary of Excluded Studies

Haematologica. 2000;85(6):564-72. Russell G, Gore CJ, Ashenden MJ, et al. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. *Eur J Appl Physiol*. 2002;86(5):442-9. Stevenson J, Krishnan S, Inigo M, et al. Echinacea-Based Dietary Supplement Does Not Increase Maximal Aerobic Capacity in Endurance-Trained Men and Women. *J Diet Suppl* 2016;13(1):324–38. Sutehall S, Martin-Rincon M, Wang G, et al. The Performance Effects of Microdose Recombinant Human Erythropoietin Administration and Carbon Monoxide Rebreathing. *Curr Sport Med Rep.* 2018;17(12):457-66. Whitehead M, Martin T, Scheett T, et al. Running economy and maximal oxygen consumption after 4 weeks of oral Echinacea supplementation. *J Strength Cond Res* 2012;26(1):1928–1933.	
Audran M, Gareau R, Matecki S, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. *Med Sci Sports Exerc.* 1999;31(5):639-45. Bornø A, Aachmann-Andersen NJ, Munch-Andersen T, et al. Screening for recombinant human erythropoietin using [Hb], reticulocytes, the OFF hr score, OFF z score and Hb z score: status of the Blood Passport. *Eur J Appl Physiol*. 2010;109(3):537-43. Clyne N, Berglund B, Egberg N. Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects. *Thromb Res.* 1995;79(1):125-29. Durussel J, Daskalaki E, Anderson M. Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men. *Eur J Appl Physiol.* 2013;8(2):e56151. Ekblom B, Berglund B. Effect of erythropoietin administration on mammal aerobic power. *Scand J Med Sci Sports.* 2007;1(2):88-93.	Absence of or inappropriate control

Appendix 2: Summary of Excluded Studies

Haile DW, Durussel J, Mekonen W, et al. Effects of EPO on Blood Parameters and Running Performance in Kenyan Athletes. *Med Sci Sports Exerc*. 2019;51(2):299-307. Juel C, Thomsen J, Rentsch R. Effects of prolonged recombinant human erythropoietin administration on muscle membrane transport systems and metabolic marker enzymes. *Eur J Appl Physiol.* 2007;102(1):41-4. Lundby C, Damsgaard. Exercise performance in hypoxia after novel erythropoiesis stimulating protein treatment. *Scand J Med Sci Sports.* 2006;16:35-40. Lundby C, Hellsten Y, Jensen M, et al. Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. *J Appl Physiol.* 2008;104(4):1154-60. Robach P, Calbet J, Thomsen J, et al. The ergogenic effect of recombinant human erythropoietin on VO2max depends on the severity of arterial hypoxemia. *PLoS One.* 2008;3(8):e2996.	
Abellan R, Remacha A, Ventura R, et al. Hematologic response to four weeks of intermittent hypobaric hypoxia in highly trained athletes. *Haematologica.* 2005;90(1):126-27. Birkhoff WA, Heuberger J, Post TE, et al. Recombinant human erythropoietin does not affect several microvascular parameters in well-trained cyclists. *Physiol Rep.* 2018;6(24):e13924. Bodary P, Pate R, Wu Q, et al. Effects of acute exercise on plasma erythropoietin levels in trained runners. *Med Sci Sports Exerc.* 1999;31(4):543-6. Borrione P, Parisi A, Salvo R, et al. A peculiar pattern of expression of the transferrin receptor (CD71) by reticulocytes in patients given recombinant human erythropoietin (rHuEPO): A novel marker for abuse in sport? *J Biol Regul Homeost Agents.* 2007;21(3-4):79-88. Caldarazza Ienco E, Carlesi C, Logerfo A, et al. Resting and exercise-related oxidative stress markers in patients under erythropoietin treatment. *Amyotroph Lateral Scler.*	Inappropriate outcome measures or analyses (e.g. outcomes not in inclusion criteria or missing between-group analysis between intervention and placebo group)

Appendix 2: Summary of Excluded Studies

2012;13(1):181. Clark B, Woolford SM, Eastwood A, et al. Temporal changes in physiology and haematology in response to high-and micro-doses of recombinant human erythropoietin. *Drug Test Anal*. 2017;9(10):1561-71. Kastner A, Grube S, El-Kordi A, et al. Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance. *Mol Med.* 2012;87(10):E90. Muza R, Jones J, Fulco C, et al. Recombinant erythropoietin administration reduces exercise-induced deline in regional cerebral oxygenation at 4500 m. *FASEB J.* 2012;26(1):lb1-1163.7. Remacha A, Ordonez J, Barcelo M, et al. Evaluation of erythropoietin in endurance runners. *Haematologica.* 1994;79(4):350-2. Viuff SL, Plenge U, Belhage B, et al. Effects of low-dose recombinant human erythropoietin treatment on cognitive performance. *Dan Med J*. 2017 1;64(9):1-5.	
Baraldi E, Montini G, Zanconato S et al. Exercise tolerance after anaemia correction with recombinant human erythropoietin in end-stage renal disease. *Pediatr Nephrol.* 1990;4(6):623-6. Braumann K, Nonnast-Daniel B, Boning D, et al. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. *Nephron.* 1991;58(2):129-34. Grunze M, Kohlmann M, Mulligan M, et al. Mechanisms of improved physical performance of chronic hemodialysis patients after erythropoietin treatment. *Am J Nephrol.* 1990;10(2):18-23. Guthrie M, Cardenas D, Eschbach J, et al. Effects of erythropoietin on strength and functional status of patients on hemodialysis. *Clin Nephrol.* 1993;39(2):97-102. Horina J, Schwaberger G, Brussee H. Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. *Nephrol Dial Transplant.* 1993;8(11):1219-22.	Comorbidities present in study population

Appendix 2: Summary of Excluded Studies

Huppmann M, Hief C, Schenk E, et al. Erythropoietin therapy in renal anemia. Effect on ergospirometry performance parameters. *Wien Med Wochenschr Suppl.* 1989;104(1):48-50. Jin B, Luo X, Lin H, et al. A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure. *Eur J Heart Fail* 2010;12(3):249-53. Mayer G, Thum J, Cada E, et al. Working capacity is increased following recombinant human erythropoietin treatment. *Kidney Int.* 1988;34(4):525-8. Nelson A, Hower C, Nguyen T, et al. Erythropoietin administration does not influence the GH--IGF axis or makers of bone turnover in recreational athletes. *Clin Endocrinol.* 2005;63(3):305-9. Normalisation of Hb level with epoetin alfa improves exercise performance in ESRD. *Erythropoiesis: new dimensions in the treatment of anaemia.* 2000;10(2):38-9. Quarello F, Martina G, Beltrame G, et al. Effects of erythropoietin on the cardiovascular system and the intradialytic hemodynamic behavior. *Minerva Urol Nefrol.* 1991;43(3):125-130.	
4th International Symposium for Hypoxia in Medical Research, Training and Rehabilitation. *Sleep Breath.* 2012;16(1). Alexy T. The pros and cons of erythropoietin use in the clinical practice. *Clin Hemorheol Microcirc.* 2013;54(2):174. Audran M, Lejeune M, Bonafoux B, et al. Analysis of human reticulocyte genes reveals altered erythropoiesis: potential use to detect recombinant human erythropoietin doping. *Haematologica.* 2004;89(8):991-7. Balestra C, Germonpré P. EPO and doping. *Eur J Appl Physiol.* 2010;109(5):1001-2. Bham B. Unhealthy competition. Advances in biomedical research provide new drugs and technologies in medicine, but also new ways for athletes to illegally enhance their performance. *EMBO Rep.* 2003;4(10);927-9.	Inappropriate study design (e.g. review article)

Appendix 2: Summary of Excluded Studies

Borrione P, Mastrone A, Salvo R. Oxygen delivery enhancers: past, present, and future. *J Endocrinol Invest.* 2008;31(2):185-92.	
Boyce E. Use and effectiveness of performance-enhancing substances. *J Pharm Pract.* 2003;16(1):22-36.	
Buemi M, Lacquaniti A, Cernaro V, et al. Down with the erythropoietin. Long live the erythropoietin! *Curr Drug Targets.* 2009;10(10):1028-32.	
Caetano Júnior P, Cunha T, Lemes L, et al. Effects of administration of human recombinant erythropoietin on physical performance: Study review. *Rev Andal Med Deport.* 2014;7(1):170-7.	
de Oliveira Carolina Dizioli R, de Bairros André V, Yonamine M. Blood Doping: Risks to Athletes' Health and Strategies for Detection. *Subst Use Misuse.* 2014;49(9):1168-81.	
Finnoff J, Chimes G, Murray T. Performance-Enhancing Drugs. *PM R.* 2010;2(4):285-93.	
Fisher J. Erythropoietin: physiology and pharmacology update. *Exp Biol Med.* 2003;228(1):1-14.	
Gaudard A, Varlet-Marie E, Bressole F, et al. Drugs for Increasing Oxygen Transport and Their Potential Use in Doping: A Review. *Sports Med.* 2003;33(3):187-212.	
Guezennec C. Doping: effective, consequences, prevention. *Ann Endocrinol.* 2001;62(1):33-41.	
Henry D. Changing patterns of care in the management of anemia. *Semin Oncol.* 1992;19(3):3-7.	
Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. *Curr Pharm Biotechnol.* 2000;1(1);11-31.	
Opie L. Erythropoietin as a cardioprotective agent: Down but	

Appendix 2: Summary of Excluded Studies

not out. *Heart*. 2011;97(19):1537-9. Sgrò P, Sansone M, Sansone A, et al. Effects of erythropoietin abuse on exercise performance. *Phys Sportsmed*. 2018;46(1):105-15. Simon T. Induced erythrocythemia and athletic performance. *Semin Hematol.* 1994;31(2):128-33. Smith K, Bleyer A, Little W, et al. The cardiovascular effects of erythropoietin. *Cardiovasc Res.* 2003;59(3):538-48. Szygula Z. Sports anaemia, regulation of erythropoietin biosynthesis during physical effort and EPO doping. *Br J Sports Med.* 2010;44(S1):i17. Thompson C, Kemp G, Taylor D, et al. Bioenergetic effects of erythropoietin in skeletal muscle. *Nephron.* 1996;74(1):239-40. Varlet-Marie E, Gaudard A, Audran M, et al. Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes. *Int J Sports Med.* 2003;24(4):252-7.	
Boyaci F, Gokmen N, Erbayraktar S, et al. Effects of erythropoietin on the volume of infarction after spinal cord ischemia model. *J Neurol Sci Turk.* 2012;29(1):101-9. Cailaud C, Mechta M, Ainge H, et al. Chronic erythropoietin treatment improves diet-induced glucose intolerance in rats. *J Endocrinol.* 2015;225(2):77-88. Cayla J, Maire P, Duvallet A, et al. Erythropoietin induces a shift of muscle phenotype from fast glycolytic to slow oxidative. *Int J Sports Med.* 2008;29(6):460-5. El-Kordi A, Radyushkin K, Enhrenreich H. Erythropoietin improves operant conditioning and stability of cognitive performance in mice. *BMC Biol.* 2009;7(73).	Use of animal models
Bellamy-Zions J. Cracking Down on EPO Drug Use. *Canadian thoroughbred.* 2014;29(7):7. Burke E. Performance enhancement: blood boosting, erythropoietin, and steroids. Philadelphia, PA: Hanley & Belfus 1994.	Not an original scientific article

Appendix 2: Summary of Excluded Studies

Hansen M. Learn how to optimize your performance like elite cyclists: the secret to improving your endurance. *Triathlete.* 2013. Jereski L. It gives athletes a boost: maybe too much: erythropoietia. *Business week.* 1989. Heuberger J, Posthuma JJ, Rotmans JI, et al. Effects of exercise and erythropoietin on thrombotic risk in well-trained cyclists [abstract]. In: 26th International Society on Thrombosis and Haemostasis Congress;2017;Germany.	